Welcome
Support Centre
11 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
An observer blind, parallel group, randomised multicentre study to compare the safety and efficacy of a new formulation of topical clindamycin phosphate in patients with mild to moderate acne
ISRCTN ISRCTN72179764
ClinicalTrials.gov identifier
Public title An observer blind, parallel group, randomised multicentre study to compare the safety and efficacy of a new formulation of topical clindamycin phosphate in patients with mild to moderate acne
Scientific title
Acronym N/A
Serial number at source ZCG/4/C
Study hypothesis To ascertain the efficacy of a new formulation of topical clindamycin gel.
Lay summary
Ethics approval Not provided at time of registration
Study design Multicentre randomised active controlled parallel group trial
Countries of recruitment United Kingdom
Disease/condition/study domain Mild to moderate acne vulgaris.
Participants - inclusion criteria Consenting patients of either sex, between 12 and 40 years of age, with mild to moderate inflammatory acne with a grade ranging from 2.0 to 7.0 (The Leeds Revised Acne Grading System, 1998).
Participants - exclusion criteria 1. Patients with significant nodulocystic acne
2. Use of systemic topical antibiotics within 4 weeks prior to the start of treatment
3. Concomitant medication which may interfere with study evaluation
Anticipated start date 19/07/1999
Anticipated end date 29/09/2000
Status of trial Completed
Patient information material
Target number of participants 270
Interventions Zindaclin® 1% Gel (twice a day [bd] & once a day [od]) and Dalacin-T® Topical Lotion (bd).
Primary outcome measure(s) The change in facial inflammatory lesion count from baseline visit to the end of treatment (week 16).
Secondary outcome measure(s) 1. The change in acne grade (The Leeds Revised Acne Grading System, 1998) from the baseline visit to the end of treatment
2. The change in number of total comedones, open comedones, closed comedomes, pustules
3. Mean change in total lesion count
4. Patient’s global assessment
5. Investigator’s global assessment
Sources of funding ProStrakan Pharmaceuticals (UK)
Trial website
Publications 2005 results in http://www.ncbi.nlm.nih.gov/pubmed/16302325
Contact name Prof  WJ  Cunliffe
  Address Department of Dermatology
Leeds General Infirmary
  City/town Leeds
  Zip/Postcode LS1 3EX
  Country United Kingdom
Sponsor ProStrakan Pharmaceuticals (UK)
  Address Buckholm Mill Brae
  City/town Galashiels
  Zip/Postcode TD1 2HB
  Country United Kingdom
Date applied 09/09/2005
Last edited 17/09/2009
Date ISRCTN assigned 06/10/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central